Cytostatic and immunomobilizing activities of polymer-bound drugs: Experimental and first clinical data

Journal of Controlled Release

Volumn 91, Issue 1-2, 2003, Pages 1-16

  Říhová, Blanka ^a   Strohalm, Jiří ^b   Prausová, Jana ^c   Kubáčková, Katerina ^c   Jelínková, Markéta ^a   Rozprimová, Lad'ka ^d   Šírová, Milada ^a   Plocová, Dana ^b   Etrych, Tomáš ^b   Šubr, Vladimír ^b   Mrkvan, Tomáš ^a   Kovář, Marek ^a   Ulbrich, Karel ^b  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^d Immunological Laboratory   (Czech Republic)

Author keywords

Breast cancer; HPMA; Human immunoglobulin; Immunomobilization; NK cells, Doxorubicin; Targeted therapy; Tumor markers

Indexed keywords

BLOOD; IMMUNOLOGY; PATIENT MONITORING; POLYMERS;

CYTOTOXIC CHEMOTHERAPY;

DRUG PRODUCTS;

AMINOGLUTETHIMIDE; ANASTROZOLE; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 72-4 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CD16 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERYTHROMYCIN ETHYLSUCCINATE; FERRITIN; FLUOROURACIL; IMMUNOGLOBULIN; INTRAGLOBIN; LEUCINE; METHOTREXATE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; NAVELBINE; PACLITAXEL; PREDNISONE; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; EXCIPIENT; HYDROXYPROPYL METHACRYLATE; IMMUNOGLOBULIN G; METHACRYLIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; POLYMER; THYMIDINE;

ADULT; ANEMIA; BLOOD SAMPLING; BREAST CARCINOMA; CASE REPORT; CONFERENCE PAPER; CYTOSTASIS; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; IMMUNOLOGICAL PARAMETERS; LEUKOPENIA; LIVER METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; MASTECTOMY; NATURAL KILLER CELL; PRIORITY JOURNAL; RETICULOCYTE; SIDE EFFECT; ANIMAL; ARTICLE; BLOOD CELL COUNT; BREAST TUMOR; CELL CULTURE; CHEMISTRY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; LIVER FUNCTION TEST; METABOLISM; MIDDLE AGED; MOUSE; SYNTHESIS;

ADULT; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; BREAST NEOPLASMS; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCIPIENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LIVER FUNCTION TESTS; MASTECTOMY; METHACRYLATES; MICE; MIDDLE AGED; POLYMERS; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 0141548120     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(03)00235-9     Document Type: Conference Paper

References (49)

1. Vasey P.A., Kaye S.B., Morrison R., Twelves Ch., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetics study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. 5:1999;83-94.
2. Maeda H., Matsumura Y. Tumouritropic and lymphotropic principles of macromolecular drugs. CRC Crit. Rev. Ther. Drug Carrier Syst. 6:1989;193-210.
3. Suzuki F., Pollard R.B., Uchimura S., Munakata T., Maeda H. Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin. Cancer Res. 50:1990;3897-3904.
4. Říhová B., Strohalm J., Kubáč ková K., Jelínková M., Hovorka O., Kovář M., Plocová D., Šírová M., Št'astný M., Rozprimová L., Ulbrich K. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. J. Controlled Release. 78:2002;97-114.
5. J. Kopeček, P. Rejmanová, J. Strohalm, K. Ulbrich, B. Říhová, V. Chytrý, J.B. Lloyd, R. Duncan, Synthetic polymeric drugs, US patent 5,037,883 (1991).
6. Říhová B., Kopeček J. Biological properties of targetable poly N-(2-hydroxypropyl) methacrylamide-antibody conjugates. J. Controlled Release. 2:1985;289-310.
7. Říhová B., Kopečková P., Strohalm J., Rossmann P., Větvička V., Kopeček J. Antibody-directed affinity therapy applied to the immune system: In vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46:1988;100-114.
8. Duncan R., Kopečková P., Strohalm J., Hume I.C., Lloyd J.B., Kopeček J. Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br. J. Cancer. 57:1988;147-156.
9. Cassidy J., Duncan R., Morrison G.J., Strohalm J., Plocová D., Kopeček J., Kaye S.B. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem. Pharmacol. 38:1989;875-879.
10. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs. 3:1992;175-210.
11. 6 toward human hepatocarcinoma cell line (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy 1.2 antibodies. J. Controlled Release. 25:1993;71-87.
12. Seymour L.W. Soluble polymers for lectin-mediated drug targeting. Adv. Drug Deliv. Rev. 14:1994;89-111.
13. Říhová B., Strohalm J., Plocová D., Šubr V., Šrogl J., Jelínková M., Šírová M., Ulbrich K. Cytotoxic and cytostatic effects of anti-Thy 1.2 targeted doxorubicin and cyclosporin A. J. Controlled Release. 40:1996;303-319.
14. Peterson C.M., Lu J.M., Sun Y., Peterson C.A., Shiah J.-G., Straight R.C., Kopeček J. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res. 56:1996;3980-3985.
15. Minko T., Kopečková P., Kopeček J. Efficacy of chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer. 86:2000;108-117.
16. 2-targeted conjugates and combined therapy with immunomodulators. J. Controlled Release. 64:2000;241-261.
17. Shoenfeld Y., Fishman P. Gamma-globulin inhibits tumor spread in mice. Int. Immunol. 11:1999;1247-1251.
18. Ulbrich K., Šubr V., Strohalm J., Plocová D., Jelínková M., Říhová B. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physicochemical characterization. J. Controlled Release. 64:2000;63-79.
19. Říhová B., Bilej M., Větvička V., Ulbrich K., Strohalm J., Kopeček J., Duncan R. Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Biomaterials. 10:1989;335-342.
20. Říhová B., Jelínková M., Strohalm J., Št'astný M., Hovorka O., Plocová D., Kovář M., Dráberová L., Ulbrich K. Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with mouse Thy-1.2 gene. Bioconjug. Chem. 11:2000;664-673.
21. Bromelow K.V., Galea-Lauri J., O'Brian M.E., Souberbielle B.E. A highly sensitive whole blood natural killer cell assay. J. Immunol. Methods. 217:1998;177-184.
22. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods. 145:1991;185-192.
23. Steel D., Whitehead A.S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol. Today. 15:1994;81-88.
24. Zach O., Kasparu H., Krieger O., Hehenwarter W., Girschikofsky M., Lutz D. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J. Clin. Oncol. 17:1999;2015-2019.
25. Barber M.D., Ross J.A., Fearon K.C. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr. Cancer. 35:1999;106-110.
26. Lauerová L., Dušek L., Šimíč ková M., Rovný F., Spurný V., Rovný F., Slampa P., Žaloudík J., Rejthar A., Wotke J., Kovařík J. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy. Neoplasma. 46:1999;141-149.
27. Nozoe T., Matsumata T., Sugimachi K. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am. J. Clin. Oncol. 23:2000;263-266.
28. Berois N., Varangot M., Aizen B., Estrugo R., Zarantonelli L., Fernandez P., Krygier G., Simonet F., Barrois E., Muse I., Osinaga E. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CD19, MUC1 and CEA using RT-PCR. Eur. J. Cancer. 36:2000;717-723.
29. Lumachi F., Brandes A.A., Boccagni P., Polistina F., Favia G., D'Amico D.F. Long-term follow up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res. 19:1999;4485-4489.
30. Huang J., Hardy J.D., Sun Y., Shively J.E. Essential role of biliary glycoprotein (CD66a) in morphogenesis of the human mammary epithelial cell line MCF10F. J. Cell Sci. 112:(Pt 23):1999;4193-4205.
31. Montelli T.C., Peracoli M.T., Gabarra R.C., Soares A.M., Kurokawa C.S. Familial cancer: depressed NK-cell cytotoxicity in healthy and cancer affected members. Arq. Neuropsiquiatr. 59:2001;6-10.
32. Sephton S.E., Sapolsky R.M., Kraemer H.C., Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl. Cancer Inst. 92:2000;994-1000.
33. Julyan P.J., Seymour L.W., Ferry D.R., Daryani S., Boivin Ch.M., Doran J., David M., Anderson D., Christodoulou Ch., Young A.M., Hesselwood S., Kerr D.J. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J. Controlled Release. 57:1999;281-290.
34. Thomson A.H., Vasey P.A., Murray L.S., Cassidy J., Fraier D., Frigerio E., Twelves C. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumors. Br. J. Cancer. 81:1999;99-107.
35. 125DNM. J. Controlled Release. 10:1989;37-49.
36. Rejmanová P., Kopeček J., Duncan R., Lloyd J.B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers. Biomaterials. 6:1985;45-48.
37. Penn I. The effect of immunosuppression on preexisting cancers. Transplant. Proc. 25:1993;1380-1382.
38. Besa E.C., Klumpe D. Prophylactic immune globulin in chronic lymphocytic leukemia. New Engl. J. Med. 326:1992;139-141.
39. Trinchieri G. Immunobiology of interleukin-12. Immunol. Res. 17:1998;269-278.
40. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., Folkman J. Inhibition of angiogenesis in vivo by interleukin-12. J. Natl. Cancer Inst. 87:1995;581-586.
41. Nishimura T., Nakui M., Sato M., Iwakabe K., Kitamura H., Sekimoto M., Ohta A., Koda T., Nishimura S. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother. Pharmacol. 46:(Suppl. S):2000;52-61.
42. Tzai T.S., Shiau A.L., Wu C.L., Tsai Y.S. Postoperative administration of interleukin-12 significantly enhances the anti-tumor immune response of MBT-2 bladder cancer bearing mice. Proc. Natl. Sci. Counc. Repub. China B. 24:2000;56-62.
43. T. Vassilev, V. Flurez, A. Pashov, C. Dubey, B. Lacroix-Desmazes, B. Bellon, Interactions of i.v. Ig with molecules and cells of the immune system, in: M.D. Kazatchkine, A. Morell (Eds.), Intravenous Immunoglobulin Research and Therapy, Parthenon, New York, p. 95.
44. Bar-Dayan Y., Barshack I., Blank M., Goldberg I., Levy Y., Kopolovic J., Fishman P., Shoenfeld Y. Antibodies to the cytoplasm, cell membrane and nuclear membrane of malignant neoplasms on pooled normal human polyspecific immunoglobulin G. Int. J. Oncol. 15:1999;1091-1096.
45. Torchilin V.P., Iakounbov L.Z., Samokhin G.P., Rammohan R., Mongayat D.A., Lukyanov A.L. Tumor cell surface-bound nucleosomes: universal molecular targets for tumoricidal autoantibodies. J. Controlled Release. 74:2001;373-375.
46. Marchalonis J.J., Kaymaz H., Dedeoglu F., Schulter S.F., Yocum D.E., Edmundson A.B. Human autoantibodies reactive with synthetic autoantigens from T cell receptor β chain. Proc. Natl. Acad. Sci. USA. 89:1992;3325-3329.
47. Hovorka O., Št'astný M., Etrych T., Šubr V., Strohalm J., Ulbrich K., Říhová B. Differences in the intracellular fate of free or polymer-bound doxorubicin. J. Controlled Release. 80:2002;101-117.
48. Říhová B. Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev. 29:1998;273-289.
49. Flanagan P.A., Duncan R., Říhová B., Šubr V., Kopeček J. Immunogenicity of protein-N-(2-hydroxypropyl)methacrylamide conjugates in A/J and B10 mice. J. Bioact. Compat. Polym. 5:1990;151-166.